ÂÜÀòÂÒÂ×

Sylvain THIERRY, PhD has extensive work experience in the field of translational research and immuno-oncology. Sylvain is currently serving as the Head of Pharmacology (Immuno-Oncology and Targeted Therapies) at Mablink Bioscience since March 2023.

Prior to that, Sylvain worked at Tollys, where they held multiple positions including Director of Translational Research (Immuno-Oncology and Innovative-Therapies) from July 2020 to March 2023, and Coordinator of Translational Research (Immuno-Oncology and Innovative-Therapies) from January 2018 to July 2020. At Tollys, they were responsible for inventing and characterizing a new TLR3-Ligand family as an innovative therapy in solid cancers. Sylvain also developed translational research using these drug-candidates in different cancer models to facilitate clinical trials.

From 2014 to 2017, Sylvain worked as the INCa Translational Project Coordinator (Immuno-Oncology and Innovative-Therapies) at Institut Curie. During this time, they conducted preclinical studies of AsiDNA/D-bait in association with arc-therapy and immunotherapy on HNSCC and investigated the effects of AsiDNA/D-bait on hematological cancers, necroptotic cell death, and immune response.

Before their time at Institut Curie, Sylvain worked as a Research Scientist CNRS/ENS (Immuno-Virology, Trans-Genetics, and Innovative-Therapies) at Ecole normale supérieure Paris-Saclay from 2008 to 2014. Their research focused on HIV-1 pre-integration latency, the role of unintegrated retroviral DNAs in viral cycle expression and integration, and the pharmacological screening of antiretroviral therapies.

Sylvain began their career as a Lecturer and Research Scientist (ATER) at Université Pierre et Marie Curie from 2006 to 2008, where they studied the role of Plasmodium falciparum inflammatory protein HMGB1 in cerebral malaria and conducted omics studies of nuclear factors involved in the differentiation of Plasmodium falciparum through its erythrocytic cycle.

Sylvain holds a PhD in Immuno-Virology from Université Paris Descartes, which they obtained in 2006.

Sylvain THIERRY, PhD, completed their education in a chronological order. Sylvain first attended CY Cergy Paris Université from 1998 to 2001, where they obtained a Maitrise (Master 1), a Licence (L3), and a DEUG (L1 and L2) in Cell and Molecular Biology. Following this, they pursued further studies at the Faculté de Pharmacie - Université Paris-Saclay from 2001 to 2002, focusing on Pharmacology, Microbiology, Pathologies, and Antiinfectious Agents. Finally, Sylvain undertook their doctoral studies at Université Paris Cité from 2002 to 2006, culminating in the award of a Doctor of Philosophy (PhD) degree in Immuno-Virology.